about
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cellsA retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma.Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.Opportunistic bilateral salpingectomy during benign gynecological surgery for ovarian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics and Gynecology.The origin of stroma surrounding epithelial ovarian cancer cells.Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by EpigeneticsBiomarkers in endometrial cancer: Possible clinical applications (Review)Polymorphisms of estrogen metabolism-related genes ESR1, UGT2B17, and UGT1A1 are not associated with osteoporosis in surgically menopausal Japanese womenFactors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancerCurrent status of molecular-targeted drugs for endometrial cancer (Review).Clinical statistics of gynecologic cancers in Japan.Narrow band imaging in gynecology: a new diagnostic approach with improved visual identification (Review).MicroRNAs in endometrial cancer.Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology.Intratumoral CD8+ Lymphocyte Infiltration as a Prognostic Factor and Its Relationship With Cyclooxygenase 2 Expression and Microsatellite Instability in Endometrial Cancer.Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients.Intravenous low-grade endometrial stromal sarcoma with intracardiac extension: A CASE OF inaccurate tumor location on contrast-enhanced computed tomographyAurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee.Clinicopathologic manifestations of early-onset endometrial cancer in Japanese women with a familial predisposition to cancer.Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.Osteoporosis is less frequent in endometrial cancer survivors with hypertriglyceridemia.Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.A Comparison of Dye Versus Fluorescence Methods for Sentinel Lymph Node Mapping in Endometrial Cancer.The importance of para-aortic lymph nodes in sentinel lymph node mapping for endometrial cancer by using hysteroscopic radio-isotope tracer injection combined with subserosal dye injection: Prospective study.Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer: comparison of magnetic resonance imaging and frozen sections.Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer.Carcinoma of the lower uterine segment diagnosed with Lynch syndrome based on MSH6 germline mutation: A case report.Use of the collagen gel droplet embedded drug sensitivity test to determine drug sensitivity against ovarian mature cystic teratoma with malignant transformation to adenocarcinoma: a case report.Pathological factors associated with omental metastases in endometrial cancer.FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in JapanRetrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancerEffective multidisciplinary treatment for ovarian granulosa cell tumor with multiple metastases--a case report[A treatment strategy for endometrial cancer]Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and GynecologyHysteroscopic transcervical resection is useful to diagnose myometrial invasion in atypical polypoid adenomyoma coexisting with atypical endometrial hyperplasia or endometrial cancer with suspicious myometrial invasion
P50
Q28271164-E786780D-4C9E-4911-9A48-3C0BFD541FEDQ33415973-6C7D6733-0C8C-4E67-B49E-F58810C29070Q33647706-B7F1C02F-359E-4F49-8649-A06BEF3113BBQ33735161-934CAF65-EC2F-4B34-816C-4CC06C7E95A4Q34497791-F1F858F2-236E-4370-81BF-B6840FBB3B25Q35882785-B12FC138-F6E5-4180-83A8-A754F2256BBFQ36084326-86D6C192-E746-4D55-8303-E11BF36F4F84Q36181886-6307C3BA-6066-4FD7-9B3A-0107A444C470Q36466930-A35B163A-FEF3-4C5C-83DD-C37A4BDFF18DQ36772954-F58A1874-7EFB-4217-8D78-3A66C45CAF7FQ37007297-C84E9B86-F918-4A36-9AB4-B44071758B6DQ37560813-24B01BD7-2604-4D2D-BD07-351C5D16F3ECQ37662473-1B082FEF-11F7-483F-8533-EBA9983CC148Q37945032-907BA62C-C798-4AB3-89AA-CE87BEF6A637Q38079122-87007CE8-90F4-4E5B-ACDA-AB0DA9AD9AAEQ40484570-25DF9BBD-3462-48C0-841A-8240735EDE06Q40797291-AD4A4DD6-0EEB-4974-9C75-1656966AFFAEQ41339278-2D77C203-930B-4502-8FAF-D1D5ABDBA1D7Q42538631-504CD5C6-F62B-4DBE-9011-F38209CAE57EQ42562915-B8BDE3A5-0B2C-44A6-9AAC-385989915F15Q42700313-6D4D8DF4-91FB-4873-9255-215AA5A548A7Q44412300-81B9D1CD-BA36-4A8C-B7AB-AB8C3FDCFB75Q47437659-BF6F5629-9704-4B03-A59A-EA82D35AB21DQ48062375-8121EF62-E7B6-4199-AE5E-9A8A449ED042Q48107265-BB7C08EA-D721-4312-927A-A2E5F6C66BACQ49650228-F43E8BC8-7543-4C84-A70B-2DA4AD288C98Q50200779-2A9A8CE0-7006-430D-9147-817AC8866FFEQ50235850-DED5BD7B-28C6-4824-AC99-524CDF964E63Q50895673-B3A09649-4AE3-4500-93AD-0019B59C741AQ51010316-AC1017E4-1D8B-4DCE-8651-639DDAE3FC32Q51280079-F2B6D036-9967-4226-8D8B-C59D3D3FB3E7Q51765983-A5A4F91A-1185-47DC-86DB-3CE172416D34Q53338160-BA7715A5-DBA7-4616-8EAC-E9E8E718EC28Q53572147-9EADE363-1B6E-461E-8EBD-F6D61C201F0CQ81341333-A1A6A4D4-AAD5-448F-A1CE-B3CD14A071F3Q83725129-74D6E74B-3AB3-44F7-AB02-6C6F5BBFC395Q85254957-0A3B22EF-B793-4F24-B2A5-1B52595547AEQ85456785-EC5E2C84-E2E8-4CA6-9E50-72D6785D3D32Q85909992-31D28FC7-CE90-42C7-9692-4E52AA11CE4DQ86221675-3A78740E-F733-42D1-8626-F1CA9A7B2163
P50
description
Japanese oncologist
@en
oncólogo japonés
@es
onderzoeker
@nl
日本の医学者、腫瘍学者
@ja
name
Wataru Yamagami
@ast
Wataru Yamagami
@en
Wataru Yamagami
@es
Wataru Yamagami
@sl
山上亘
@ja
type
label
Wataru Yamagami
@ast
Wataru Yamagami
@en
Wataru Yamagami
@es
Wataru Yamagami
@sl
山上亘
@ja
prefLabel
Wataru Yamagami
@ast
Wataru Yamagami
@en
Wataru Yamagami
@es
Wataru Yamagami
@sl
山上亘
@ja
P1053
D-7754-2014
P106
P108
P21
P31
P3829
P496
0000-0003-3925-6057
P569
2000-01-01T00:00:00Z